Farnesoid X receptor agonists for primary biliary cirrhosis

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose of review: This review will provide an overview of the role of nuclear receptors in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic use in cholestatic liver diseases. Recent findings: Nuclear receptors have emerged as important mediators of a variety of metabolic and transport functions involving the liver. The role of FXR, in particular, has come to light because of its important role in bile acid homeostasis. The use of potent FXR ligands has recently been shown to offer potentially important therapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic liver disease of adults. This recent finding has now opened the door for future therapeutic trials for use of FXR agonists such as obeticholic acid for the treatment of chronic cholestatic liver diseases. Summary: Further understanding of the role of farnesoid X receptor agonists and the potential role of ligands in animal models of other forms of cholestasis will be important to set the stage for future applications to human disease.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalCurrent Opinion in Gastroenterology
Volume27
Issue number3
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Liver Diseases
Therapeutic Uses
Cytoplasmic and Nuclear Receptors
Bile Acids and Salts
Homeostasis
Ligands
Cholestasis
Animal Models
Liver
Therapeutics

Keywords

  • farnesoid X receptor
  • nuclear receptors
  • primary biliary cirrhosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Farnesoid X receptor agonists for primary biliary cirrhosis. / Lindor, Keith.

In: Current Opinion in Gastroenterology, Vol. 27, No. 3, 05.2011, p. 285-288.

Research output: Contribution to journalArticle

@article{7a8bac6df9384405b4541500a33c9304,
title = "Farnesoid X receptor agonists for primary biliary cirrhosis",
abstract = "Purpose of review: This review will provide an overview of the role of nuclear receptors in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic use in cholestatic liver diseases. Recent findings: Nuclear receptors have emerged as important mediators of a variety of metabolic and transport functions involving the liver. The role of FXR, in particular, has come to light because of its important role in bile acid homeostasis. The use of potent FXR ligands has recently been shown to offer potentially important therapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic liver disease of adults. This recent finding has now opened the door for future therapeutic trials for use of FXR agonists such as obeticholic acid for the treatment of chronic cholestatic liver diseases. Summary: Further understanding of the role of farnesoid X receptor agonists and the potential role of ligands in animal models of other forms of cholestasis will be important to set the stage for future applications to human disease.",
keywords = "farnesoid X receptor, nuclear receptors, primary biliary cirrhosis",
author = "Keith Lindor",
year = "2011",
month = "5",
doi = "10.1097/MOG.0b013e32834452c8",
language = "English (US)",
volume = "27",
pages = "285--288",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Farnesoid X receptor agonists for primary biliary cirrhosis

AU - Lindor, Keith

PY - 2011/5

Y1 - 2011/5

N2 - Purpose of review: This review will provide an overview of the role of nuclear receptors in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic use in cholestatic liver diseases. Recent findings: Nuclear receptors have emerged as important mediators of a variety of metabolic and transport functions involving the liver. The role of FXR, in particular, has come to light because of its important role in bile acid homeostasis. The use of potent FXR ligands has recently been shown to offer potentially important therapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic liver disease of adults. This recent finding has now opened the door for future therapeutic trials for use of FXR agonists such as obeticholic acid for the treatment of chronic cholestatic liver diseases. Summary: Further understanding of the role of farnesoid X receptor agonists and the potential role of ligands in animal models of other forms of cholestasis will be important to set the stage for future applications to human disease.

AB - Purpose of review: This review will provide an overview of the role of nuclear receptors in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic use in cholestatic liver diseases. Recent findings: Nuclear receptors have emerged as important mediators of a variety of metabolic and transport functions involving the liver. The role of FXR, in particular, has come to light because of its important role in bile acid homeostasis. The use of potent FXR ligands has recently been shown to offer potentially important therapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic liver disease of adults. This recent finding has now opened the door for future therapeutic trials for use of FXR agonists such as obeticholic acid for the treatment of chronic cholestatic liver diseases. Summary: Further understanding of the role of farnesoid X receptor agonists and the potential role of ligands in animal models of other forms of cholestasis will be important to set the stage for future applications to human disease.

KW - farnesoid X receptor

KW - nuclear receptors

KW - primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=79955055532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955055532&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32834452c8

DO - 10.1097/MOG.0b013e32834452c8

M3 - Article

C2 - 21297469

AN - SCOPUS:79955055532

VL - 27

SP - 285

EP - 288

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -